UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000009125
Receipt number R000010182
Scientific Title Phase II/III Trial of Postoperative Chemoradiotherapy Comparing 3-Weekly Cisplatin with Weekly Cisplatin in High-risk Patients with Squamous Cell Carcinoma of Head and Neck (JCOG1008, HNC-Adjuvant CDDP+RT-P3)
Date of disclosure of the study information 2012/10/16
Last modified on 2021/01/05 16:30:46

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase II/III Trial of Postoperative Chemoradiotherapy Comparing 3-Weekly Cisplatin with Weekly Cisplatin in High-risk Patients with Squamous Cell Carcinoma of Head and Neck (JCOG1008, HNC-Adjuvant CDDP+RT-P3)

Acronym

Phase II/III Trial of Postoperative Chemoradiotherapy Comparing 3-Weekly Cisplatin with Weekly Cisplatin in High-risk Patients with Squamous Cell Carcinoma of Head and Neck (JCOG1008, HNC-Adjuvant CDDP+RT-P3)

Scientific Title

Phase II/III Trial of Postoperative Chemoradiotherapy Comparing 3-Weekly Cisplatin with Weekly Cisplatin in High-risk Patients with Squamous Cell Carcinoma of Head and Neck (JCOG1008, HNC-Adjuvant CDDP+RT-P3)

Scientific Title:Acronym

Phase II/III Trial of Postoperative Chemoradiotherapy Comparing 3-Weekly Cisplatin with Weekly Cisplatin in High-risk Patients with Squamous Cell Carcinoma of Head and Neck (JCOG1008, HNC-Adjuvant CDDP+RT-P3)

Region

Japan


Condition

Condition

locally advanced squamous cell carcinoma of the head and neck

Classification by specialty

Hematology and clinical oncology Oto-rhino-laryngology Radiology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To test the non-inferioirity of concurrent chemoradiotherapy with weekly CDDP as compared to concurrent chemoradiotherapy with 3-weekly CDDP in overall survival for postoperative high risk patients with locally advanced squamous cell carcinoma of the head and neck

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase

Phase II,III


Assessment

Primary outcomes

overall survival (phase III), proportion of treatment completion (phase II)

Key secondary outcomes

relapse-free survival, local relapse-free survival, nutrition support free survival, adverse events, non-hospitalized treatment period during permissible treatment period, non-hospitalized treatment period during 90 days after the start of protocol treatment


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

YES

Institution consideration

Institution is considered as adjustment factor in dynamic allocation.

Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine Maneuver

Interventions/Control_1

A: Concurrent chemoradiotherapy with 3-Weekly CDDP (CDDP 100 mg/m2:day 1, 22, 43, fractionated radiation therapy: 66 Gy/33 Fr; Both 3D-CRT and IMRT are allowed.)

Interventions/Control_2

B:Concurrent chemoradiotherapy with Weekly CDDP (CDDP 40 mg/m2:day 1, 8, 15, 22, 29, 36, 43, fractionated radiation therapy: 66 Gy/33 Fr; Both 3D-CRT and IMRT are allowed.)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >=

Gender

Male and Female

Key inclusion criteria

1) Histologically proven squamous cell carcinoma in resected specimen
2) Primary lesion located at oral cavity, oropharynx, hypopharynx, or larynx.
3) Pathological stage III, IVA or IVB (UICC 7th edition)
4) high risk of locoregional recurrence defined as fulfilling i) and/or ii) by pathological specimen after tumor resection and neck lymph node dissection
i) Microscopically positive resection margin
ii) Extracapsular nodal extension
5) Within 56 days from surgery.
6) No distant metastasis in computed tomography within 28 days before registration
7) Aged 20 to 75 years old
8) ECOG performance status (PS) of 0 or 1.
9) No prior radiation therapy, chemotherapy, nor hormonal therapy
10) Adequate organ functions
11) No clinically significant abnormal findings on electrocardiogram (ECG) within 28 days from the date of registration
12) Written informed consent

Key exclusion criteria

1) Simultaneous or metachronous (within 5 years) double cancers except carcinoma in situ or intramucosal tumor.
2) Active systemic infections to be treated.
3) Body temperature of 38 or more degrees Celsius
4) Women during pregnancy, possible pregnancy, or breast-feeding
5) Psychiatric disease
6) Continuous systemic steroid treatment
7) Uncontrolled diabetes mellitus
8) History of unstable angina pectoris or myocardial infarction within 6 months
9) Uncontrolled hypertension
10) Pleural effusion, pericardiac effusion, or ascites to be drained
11) Positive HBs antigen
12) Impossiblility to refrain from smoking or drinking during protocol treatment

Target sample size

260


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Makoto Tahara

Organization

National Cancer Center Hospital East

Division name

Division of Head and Neck Medical Oncology

Zip code


Address

6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, JAPAN

TEL

04-7133-1111

Email

matahara@east.ncc.go.jp


Public contact

Name of contact person

1st name
Middle name
Last name Naomi Kiyota

Organization

JCOG1008 Coordinating Office

Division name

Department of Medical Oncology and Hematology, Kobe University Hospital

Zip code


Address

7-5-2,Kusunoki-cho,Chuo-ku,Kobe,Hyogo, 650-0017,Japan

TEL

078-382-5111

Homepage URL

http://www.jcog.jp/

Email

JCOG_sir@ml.jcog.jp


Sponsor or person

Institute

Japan Clinical Oncology Group (JCOG)

Institute

Department

Personal name



Funding Source

Organization

Japan Agency for Medical Research and Development

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

北海道大学病院(北海道)
岩手医科大学(岩手県)
東北大学病院(宮城県)
宮城県立がんセンター(宮城県)
福島県立医科大学附属病院(福島県)
自治医科大学(栃木県)
埼玉県立がんセンター(埼玉県)
埼玉医科大学国際医療センター(埼玉県)
国立がん研究センター東病院(千葉県)
国立がん研究センター中央病院(東京都)
国立病院機構東京医療センター(東京都)
東京医科歯科大学(東京都)
東京慈恵会医科大学附属病院(東京都)
がん研究会有明病院(東京都)
東京大学医学部(東京都)
横浜市立大学附属病院(神奈川県)
東海大学医学部(神奈川県)
静岡県立静岡がんセンター(静岡県)
愛知県がんセンター中央病院(愛知県)
名古屋大学医学部(愛知県)
京都大学医学部附属病院(京都府)
近畿大学医学部(大阪府)
大阪国際がんセンター(大阪府)
神戸大学医学部(兵庫県)
兵庫県立がんセンター(兵庫県)
奈良県立医科大学(奈良県)
広島大学病院(広島県)
国立病院機構四国がんセンター(愛媛県)


Other administrative information

Date of disclosure of the study information

2012 Year 10 Month 16 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2012 Year 08 Month 09 Day

Date of IRB

2012 Year 09 Month 27 Day

Anticipated trial start date

2012 Year 10 Month 16 Day

Last follow-up date

2025 Year 04 Month 16 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2012 Year 10 Month 16 Day

Last modified on

2021 Year 01 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010182


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name